Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care

NCT02638389 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Vascular Malformations

Interventions

DRUG: Sirolimus

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain